Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Belimumab Stories

2009-07-01 06:00:00

ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Senior management will host a conference call to discuss the results on Monday, July 20,...

2009-06-19 06:00:00

- Trial conducted by Novartis evaluating safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination with...

2009-06-11 06:00:00

- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy - - No increase in overall adverse events, serious adverse events, malignancies or serious infections over time - ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome...

2009-05-21 06:00:00

- First-in-class treatment for inhalation anthrax - ROCKVILLE, Md., May 21 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its human monoclonal antibody drug ABthrax(TM) (raxibacumab) for the treatment of inhalation anthrax. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) The BLA submission includes the results of two...

2009-04-29 15:05:00

- First HGS product sales achieved with delivery of ABthrax(TM) to U.S. Strategic National Stockpile - - $177 million in first quarter revenues; cash balance of $397 million as of March 31, up $24 million from year-end 2008 - - Positive results for second Phase 3 trial of Albuferon(R) in chronic hepatitis C; global marketing applications planned in fall 2009 - - Initiation of Syncria(R) Phase 3 program brings $9 million milestone payment from GSK - ROCKVILLE, Md., April 29...

2009-04-25 09:00:00

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events across the two Phase 3 trials, versus peginterferon alfa-2a - - Submission of global marketing applications planned in fall 2009 - ROCKVILLE, Md., April 25 /PRNewswire-FirstCall/...

2009-03-25 06:16:00

ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "The rapid...

2009-03-17 14:38:00

WASHINGTON, March 17 /PRNewswire/ -- The 3rd Annual Walk for Lupus Now Washington will occur on Saturday, April 18 from 9:00 a.m. to 12:00 noon on Pennsylvania Avenue, N.W. between 13th and 3rd Streets. The Lupus Foundation of America Greater Washington Chapter (LFAGW) chapter expects this year's turnout to double, reflective of the 70,000+ people with lupus in the Washington area out of more than 1.5 million in the U.S. Lupus is a chronic, autoimmune disease with no known cure that can...

2009-02-26 15:11:00

- Positive results for first Albuferon(R) Phase 3 trial announced in December 2008; data from second trial expected March 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes initiated by GlaxoSmithKline (GSK) - - $106 million of convertible debt repurchased for $50 million in cash - - 2009 revenue expected to grow to $250 million; at least $150 million from delivery of ABthrax(TM) to Strategic National Stockpile - ROCKVILLE, Md., Feb. 26...

2009-02-17 08:16:00

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that GlaxoSmithKline (NYSE: GSK) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria(R) (albiglutide) in the long-term treatment of type 2 diabetes mellitus. As a result, HGS will receive a $9 million milestone payment in the first quarter of 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "We are delighted...